Key Highlights

  • Bicara Therapeutics (NASDAQ:BCAX) plunged 45% on October 28, 2026, the largest unexplained biotech drop of the day, according to published market data. The drop shows how sharply a small-cap biotech can move without a public trigger.
  • Inhibrx Biosciences (NASDAQ:INBX) fell 24% the same day, making the two the largest unexplained biotech declines, and no news explaining either was found. The move in the second stock is separate evidence and does not establish a shared cause.
  • The cause of both drops is not verified, and this article does not offer a reason. Readers should rely on company filings for any later explanation.
  • A 45% fall in one session erases nearly half of a company's market value, so Bicara Therapeutics (NASDAQ:BCAX) holders face a sharp reset with no disclosed trigger.

What Happened on October 28

Bicara Therapeutics (NASDAQ:BCAX) fell 45% on October 28, 2026, according to published market data. Inhibrx Biosciences (NASDAQ:INBX) fell 24% on the same day. They were the two largest unexplained biotech declines of the session, meaning that a search of company releases and filings found no announcement or news item linked to the moves. The cause of both drops is not verified, and this article does not offer one. The absence of a news item does not prove there is no cause: a company can disclose a development later, and large trades can precede it. Even when a company stays silent, filings made later can reveal what drove the move.

What Unexplained Drops Usually Involve

When a stock falls sharply without a headline, analysts typically check a short list of places: new company filings, clinical trial registry updates, regulatory agency notices, and moves in related names. Clinical-stage biotechs are especially exposed because one data point can change the value of the whole company, and holders may trade ahead of formal disclosure. Which, if any, of these applies here is not known from the data reviewed, and listing them is not a claim about either company. A move of this size is also a reminder that small-cap biotechs have thin liquidity, so selling can push prices down quickly. Selling by a large holder or a change in index membership can also move thinly traded shares, though that is not claimed here.

Risks and What to Watch

The main risk for Bicara Therapeutics (NASDAQ:BCAX) holders is uncertainty: until an explanation appears, the drop could be a transient overreaction or the first sign of a bigger issue. A company that falls this far may also face financing difficulty, because raising equity at a lower price is more dilutive. Watch for any Form 8-K, press release or trial update from Bicara or Inhibrx, and for the regular-session open on October 29. Investors should avoid assuming a cause. Broader sentiment was weak, with Nasdaq-100 futures down 1.2% at 4:09 a.m. ET on October 29. A further rebound or fall at the open would add information.

Where Things Stand

Nobody has verified a reason. Bicara Therapeutics (NASDAQ:BCAX) fell 45% on October 28, 2026, and Inhibrx fell 24%, the two largest unexplained biotech drops of the day, and no news item was found for either. This article deliberately does not offer a cause. The next step is a company disclosure or filing; until one appears, the moves remain unexplained and the risk of further volatility is high.